Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) and Mediq have signed an agreement on the sale of DiaExpert. DiaExpert is an established specialist and mail-order retailer for the care of people with diabetes in Germany, specialised in insulin pump therapy. With the sale, DiaExpert will remain as a helping hand for customers and health insurers and will continue its services. Ypsomed is focusing more strongly on the development, manufacture and sale of its own high-quality medical technology products for people with chronic conditions.

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases.

Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system to pharmaceutical customers.

Press Releases Ypsomed Group

Burgdorf – Ypsomed launches bolus delivery from the smartphone on the mylife YpsoPump via the mylife App. This new feature enables mylife YpsoPump users to deliver the bolus insulin conveniently and discreetly via their personal smartphone, without having to interact with the pump itself. Following the early summer launch of automated insulin delivery (AID) via the mylife CamAPS FX App, Ypsomed now offers an additional option for discreet remote bolus delivery to all users. People with diabetes now have the freedom to choose their preferred therapy solution.

Press Releases Ypsomed Group

Burgdorf – Ypsomed's Annual General Meeting on 29 June 2022 approved all the proposals of the Board of Directors. It elected Gilbert Achermann as the new Chairman of the Board of Directors and Simon Michel as a new member of the Board of Directors. The founder and long-standing Chairman Dr. h.c. Willy Michel was given a ceremonial farewell.